Roche’s Kadcyla (trastuzumab emtansine) Receives FDA’s Expanded Approval as an Adjuvant Treatment for HER2+ Early Breast Cancer in the US
Shots:
- The approval is based on P-III KATHERINE study results assessing Kadcyla versus Herceptin in patients with HER2+ early breast cancer (eBC) with the residual invasive disease after neoadjuvant treatment included Herceptin and taxane-based CT
- The P-III KATHERINE study results: reduction in risk of breast cancer recurrence (50%); @3yrs. iDFS (88.3% vs 77.0%); absolute improvement (11.3%); worse prognosis in patients with residual disease after neoadjuvant treatment
- Kadcyla (trastuzumab emtansine) is an ADC, a combination of trastuzumab and DM1, delivering CT directly to HER2+ cancer cells. It has received approval in 104 countries including the US & EU for HER2+ m-breast cancer and is developed using ADC technology licensed from ImmunoGen
Click here to read full press release/ article | Ref: Roche | Image: Behance